- Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
- Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
- Rigel Reports First Quarter 2025 Financial Results and Provides . . .
Rigel continues to advance its Phase 1b clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of R289 in patients with relapsed or refractory (R R) lower-risk MDS
- Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting . . .
Rigel Pharmaceuticals, Inc (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
- Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib . . .
Rigel Pharmaceuticals, Inc (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
- Rigel Reports Third Quarter 2024 Financial Results and Provides . . .
"2024 has been a significant year for Rigel, marked by the acquisition of GAVRETO, our third commercial product, strong revenue growth across our commercial portfolio, and the advancement of our development pipeline," said Raul Rodriguez, Rigel's president and CEO
- Rigel Announces Conference Call and Webcast to Report First Quarter . . .
Rigel Pharmaceuticals, Inc (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
- Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for . . .
Rigel Pharmaceuticals, Inc (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
|